Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.RxElite has entered into an agreement with NPIL Pharma to fund up to $5 million through a secured subordinated debt agreement, of which $3 million was advanced to RxElite at closing.
Subscribe to our email newsletter
Jonathan Houssian, CEO and founder of RxElite, said: “This investment by NPIL Pharma will allow us to maintain our strong momentum in our Sevoflurane business through continued investment in anesthetic vaporizers and implementation of key customer contracts.”
RxElite develops, manufactures and markets generic prescription drug products in specialty generic markets.